-+ 0.00%
-+ 0.00%
-+ 0.00%

Insilico Medicine nominates oral Lp(a) inhibitor ISM0900 as preclinical candidate for cardiovascular risk management

PUBT·08/12/2026 12:34:13
Listen to the news
Insilico Medicine nominates oral Lp(a) inhibitor ISM0900 as preclinical candidate for cardiovascular risk management
  • Insilico Medicine nominated ISM0900 as a preclinical candidate for cardiovascular risk management by targeting lipoprotein(a) assembly.
  • Preclinical data showed nanomolar activity, 83.9% Lp(a) reduction, peak effect by Day 4 in animal models.
  • Compound showed oral pharmacokinetics, wide safety margins, projected lower efficacious human dose versus similar clinical-stage candidates.
  • Nomination marked Insilico’s ninth preclinical candidate disclosed since 2026, underscoring faster early-stage output from its AI platform.
  • Company cited no approved Lp(a)-lowering therapies, positioning oral small molecules as a potential opportunity in dyslipidemia.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608120830PR_NEWS_USPR_____CN23756) on August 12, 2026, and is solely responsible for the information contained therein.